American Century Companies Inc. Cuts Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

American Century Companies Inc. reduced its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 79.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,627 shares of the company’s stock after selling 21,428 shares during the quarter. American Century Companies Inc.’s holdings in Janux Therapeutics were worth $236,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in JANX. China Universal Asset Management Co. Ltd. raised its position in shares of Janux Therapeutics by 82.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock worth $367,000 after buying an additional 4,400 shares during the period. Capstone Investment Advisors LLC acquired a new stake in Janux Therapeutics in the 1st quarter valued at $1,969,000. Lester Murray Antman dba SimplyRich acquired a new stake in Janux Therapeutics in the 1st quarter valued at $300,000. ProShare Advisors LLC acquired a new stake in Janux Therapeutics in the 1st quarter valued at $251,000. Finally, Lord Abbett & CO. LLC acquired a new stake in Janux Therapeutics in the 1st quarter valued at $20,420,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $45.02 on Friday. The business has a 50-day moving average of $43.84 and a 200-day moving average of $44.67. The company has a market capitalization of $2.33 billion, a PE ratio of -36.80 and a beta of 3.54. Janux Therapeutics, Inc. has a 1-year low of $5.65 and a 1-year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. The company had revenue of $8.90 million during the quarter, compared to the consensus estimate of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The firm’s quarterly revenue was up 709.1% compared to the same quarter last year. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $46.24, for a total value of $44,297.92. Following the completion of the transaction, the insider now directly owns 6,887 shares in the company, valued at approximately $318,454.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $46.24, for a total value of $44,297.92. Following the completion of the transaction, the insider now directly owns 6,887 shares in the company, valued at $318,454.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00. Following the completion of the transaction, the chief executive officer now owns 307,054 shares of the company’s stock, valued at approximately $14,219,670.74. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 393,767 shares of company stock worth $17,857,979. Corporate insiders own 35.40% of the company’s stock.

Analyst Upgrades and Downgrades

JANX has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a report on Monday, August 19th. Scotiabank lowered their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Stifel Nicolaus initiated coverage on Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a report on Monday, September 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $66.13.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.